SignalCorporate
BIIB's Q3 Earnings Beat, New Drugs Aid Sales, '26 EPS View Tightened
Q3 earnings beat and new drug sales drove the tightened 2026 EPS view.
Context
What happened: Biogen reported third-quarter 2026 adjusted EPS of $2.62 and revenues of $2.80 billion, beating Zacks Consensus Estimates on both, and tightened its 2026 adjusted EPS guidance range.
Key numbers: Adjusted EPS $2.62 vs. estimate $2.06, down 46% year over year.
Why it matters: Growth products including Empaveli, Qalsody, Skyclarys, Spinraza, Syfovre, Zurzuvae and Leqembi collaboration revenues rose almost 50% year over year and surpassed the legacy multiple sclerosis portfolio, while declining MS and biosimilar sales and higher costs weigh on profitability.
Market: -1.8% today ($248.25), +39.6% YTD, 0.6x vol — as of 17:47 UTC
Verified: Q3_2026 (Oct 28) EPS $2.62 vs $1.98 est, +32.5% beat; next print ~Jan 27
What changed
Biogen reported third-quarter 2026 adjusted EPS of $2.62 and revenues of $2.80 billion, beating Zacks Consensus Estimates on both, and tightened its 2026 adjusted EPS guidance range.
Why it matters
Growth products including Empaveli, Qalsody, Skyclarys, Spinraza, Syfovre, Zurzuvae and Leqembi collaboration revenues rose almost 50% year over year and surpassed the legacy multiple sclerosis portfolio, while declining MS and biosimilar sales and higher costs weigh on profitability.
Market: -1.8% today ($248.25), +39.6% YTD, 0.6x vol — as of 17:47 UTC
Verified: Q3_2026 (Oct 28) EPS $2.62 vs $1.98 est, +32.5% beat; next print ~Jan 27